HAVN Life Sciences Inc. announced that it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (Revive) for use in clinical research studies. The company previously signed a supply agreement with Revive in October, 2021. In fulfilling of the purchase order, HAVN Life will export naturally derived GMP psilocybin extract from its facility in Jamaica into the U.S. through its distribution partner, Mycrodose Therapeutics Inc. ("Mycrodose") for use by the University of Wisconsin-Madison ("UW-Madison"), a Contract Research Organization ("CRO") for Revive.

This shipment of naturally derived psilocybin will allow UW-Madison to conduct research and formulation work to finalize dosing and delivery mechanisms in support of the various studies to be sponsored by Revive using an oral-thin and Hydra-gel delivery systems of psychedelics to treat mental health disorders.